Dr. Mark Skousen says the same setup is here once again.
November 2, 2026 Bonus Content: Xpeng Crossed 50,000 Monthly Deliveries. Now Comes the Hard Part....
Vertex Has Three Growth Lines. Many Investors Still Price One.
Healthcare is absorbing capital leaving AI software, and Vertex reports tonight with Journavx, a kidney-drug FDA date, and ALYFTREK's expansion…
OpenAI Set a Price. Wall Street Has to Decide If It Believes It.
A $150 billion valuation cut in six weeks is turning one private fundraise into a referendum on every AI multiple…
Chevron proved it worked. Then killed it.
November 1, 2026 Bonus Content: Walmart’s Holiday Moment Arrives as Forecasters Split A note from...
Logan Says Two Hikes. The Bond Market Is Pricing Something Else.
The Fed's hawks have stopped fighting over December and started fighting over the terminal rate. That shift is what portfolio…
Gilead and Incyte Surged When the Nasdaq Fell. Take Note.
Biotech and healthcare led the week while software slid. Was it real rotation or just timing?
8 altcoins beat Bitcoin 3x-6 fell a week later
October 31, 2026 Bonus Content: Qualcomm’s Cars Are Carrying the Company as Apple Walks Out...
Brent Settles at $117.64 With Nov. 4 on the Calendar
A limpet-mine hit in Hormuz and a U.S. warning about post-election strikes give oil traders a hard deadline.
BP’s $8.5bn Quarter Is Real. Do Exxon and Chevron Match It?
With Brent at $116 and war-risk insurance surging, energy managers are modeling what earnings look like if Hormuz normalizes.
Intel’s Foundry Customers Are Warming Up. The Stock Is Down 21% Anyway.
The Q3 call delivered progress on 18A-P and packaging. The market is focused somewhere else.